Advertisement

Prothrombin time, activated partial thromboplastin time and platelet counts of type II diabetes mellitus: a comparative study

  • Yitayal Amogne Ambelu
  • Melashu Balew Shiferaw
  • Molla Abebe
  • Bamlaku Enawgaw
Research Article
  • 108 Downloads

Abstract

Background

The incidence of cardiovascular disease due to thrombosis is 2–4 folds greater in diabetic patients. Prothrombin time, activated partial thromboplastin time and platelet count are hematological indices that give an insight into the coagulation status. Hence, this study aims to assess the coagulation status of type II diabetic patients.

Methods

A comparative cross-sectional study was conducted at Bahir Dar Felege Hiwot referral hospital, Northwest Ethiopia. A total of 40 treated type II diabetic, 40 untreated diabetics and 40 non-diabetic subjects were included. After taking informed consent, structured questionnaire was used to collect socio-demographic data. Following interview, 4 ml of blood was collected to determine PT, aPTT and platelet count of the three groups. The data were entered into SPSS version 20 and analyzed. One-way ANOVA was used to compare means of PT, aPTT and platelet count among the groups. A P value less than 0.05 was considered as statistically significant.

Results

The mean aPTT of non-diabetic, treated and untreated type II diabetic patient was 32.8 ± 4.12 s, 34.4 ± 5.3 s, and 25.42 ± 8.46 s, respectively. The proportion of untreated diabetic patients with normal PT, aPTT and platelet counts was 60.0%, 7.5 and 92.5%, respectively. There was a significant shortening of aPTT in untreated diabetic as compared to both treated and non-diabetic controls (P < 0.001).

Conclusions

Shortening of aPTT in untreated type II diabetic patients might be useful marker in patients with diabetes. Therefore, monitoring the aPTT in newly diagnosed diabetic patients is important.

Keywords

Activated partial thromboplastin time Platelet count Prothrombin time Type II diabetes mellitus Bahir Dar Ethiopia 

Abbreviations

aPTT

activated partial thromboplastin time

CVD

cardiovascular disease

DM

diabetes mellitus

FBS

fasting blood sugar

IDF

international diabetic federation

PT

prothrombin time

RBS

random blood sugar

Notes

Acknowledgements

The authors would like to thank Bahir Dar Felege Hiwot referral hospital management and laboratory staff for kind cooperation during data collection. We also thank study participants for their willingness to participate in this study and provision of important information.

Authors’ contributions

YAA participated in the design of the study, data collection, performed the statistical analysis and drafted the manuscript. MBS, MA and BE analyze and interpreted the data, and wrote the manuscript. All authors read and approved the final manuscript.

Compliance with ethical standards

Ethical consideration

This study was reviewed and approved by the School of Biomedical and Laboratory Sciences Research and Ethical Committee, College of Medicine and Health Sciences, University of Gondar. Then, after official permission was obtained from Bahir Dar Felege Hiwot referral hospital, written informed consent was obtained from every individual prior to enrolment in the study. The purpose and objectives of the study was clearly explained to the study subjects. The respondent was allowed to quit if he/she didn’t want to participate in the study. Confidentiality was maintained and withdraw at any time was allowed.

Competing interest

The authors declare that there is no conflict of interests regarding the publication of this manuscript.

Consent for publication

Not applicable. This manuscript does not contain any individual persons’ data.

References

  1. 1.
    Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, et al. Report of the committee on the classification and diagnosis criteria of diabetes mellitus. J Diabetes Invest. 2010;1(5):212–28.CrossRefGoogle Scholar
  2. 2.
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(S1):S81–90.CrossRefGoogle Scholar
  3. 3.
    International Diabetes Federation. IDF Diabetes Atlas 6th Edition. 2013; Available from: https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/19-atlas-6th-edition.html.
  4. 4.
    Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137–49.CrossRefPubMedGoogle Scholar
  5. 5.
    Carr ME. Diabetes mellitus: a hyper coagulable state. J Diabet Complicat. 2001;15(1):44–54.CrossRefGoogle Scholar
  6. 6.
    Ng VL. Prothrombine time and partial thromboplastin time assay considerations. Clin Lab Med. 2009;29:253–63.CrossRefPubMedGoogle Scholar
  7. 7.
    VanVoorhis CRW, Morgan BL. Understanding power and rules of thumb for determining sample sizes. Tutorials in Quantitative Methods for Psychology. 2007;3(2):43–50.CrossRefGoogle Scholar
  8. 8.
    HUMANGmbH. HumaClot Duoplus User Manual. HUMAN GmbH, Germany.Google Scholar
  9. 9.
    HUMANGmbH. Huma-Count hematology analyzerUser Manual. HUMAN GmbH, Germany.Google Scholar
  10. 10.
    Zhao Y, Zhang J, Zhang J, Wu J. Diabetes mellitus is associated with shortened activated partial thromboplastin time and increased fibrinogen values. PLoS One. 2011;6:1–4.Google Scholar
  11. 11.
    Chavan PS, Afroz S, Jadhav S. A comparative study of coagulation tests in type 2 diabetes mellitus individuals and health individuals. Int J Med Sci. 2014;3(1):290–8.Google Scholar
  12. 12.
    Acang N, Jalil FD. Hypercoagulation in diabetes mellitus. The Southeast Asian journal of tropical medicine and public health. 1993;24(Suppl 1):263–6.PubMedGoogle Scholar
  13. 13.
    Ankalayya B, Sodhi HS, Modala S, Baghel M. A comparative study of coagulation time in type 2 diabetes mellitus and healthy individuals. International Journal of Contemporary Medical Research. 2016;3(11):3170–1.Google Scholar
  14. 14.
    Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. Eng J Med. 2010;362:800–11.CrossRefGoogle Scholar
  15. 15.
    Lippi G, Franchini M, Targher G, Montagnana M, Salvagno G, Guidi G, et al. Epidemiological association between fasting plasma glucose and shortened APTT. Clin Biochem. 2009;42:118–20.CrossRefPubMedGoogle Scholar
  16. 16.
    Mard-Soltani M, Dayer MR, Ataie G, Moazedi AA, Dayer MS, Alavi SMR. Coagulation factors evaluation in NIDDM patient. Am J Biochem Mol Biol. 2011;1(3):244–54.CrossRefGoogle Scholar
  17. 17.
    Tripodi A, Chantarangkul V, Martinelli I, Bucciarelli P, Mannucci P. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. J American Society ofHaematology. 2004;104(12):3631–4.Google Scholar
  18. 18.
    Mwambungu A, Kaile T, Korolova L, Kwenda J, Marimo C. APTT: a screening test for hypercoagulability in type 2 diabetes mellitus patients. Medical Journal of Zambia. 2013;40(3):112–20.Google Scholar
  19. 19.
    Ifeanyi OE, Chukwuemeka OH, Sunday AG, Uche EC. Changes in some coagulation parameters among diabetic patients in Michael Okpara university of agriculture, Umudike, Abia state, Nigeria. World journal of pharmacy and pharmaceutical sciences. 2014;3(4):52–61.Google Scholar
  20. 20.
    Ephraim RK, Awuku YA, Adu P, Ampomah LT, Adoba P, Panford S, et al. High risk of coagulopathy among Type-2 diabetes mellitus clients at a municipal hospital in Ghana. Ghana medical journal. 2017;51(3):101–7.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Yitayal Amogne Ambelu
    • 1
    • 4
  • Melashu Balew Shiferaw
    • 2
  • Molla Abebe
    • 3
  • Bamlaku Enawgaw
    • 4
  1. 1.Department of Laboratory, College of Health SciencesDebretabor UniversityDebre TaborEthiopia
  2. 2.Amhara Public Health InstituteBahir DarEthiopia
  3. 3.College of Medicine and Health Science, School of Biomedical and Laboratory Sciences, Department of Clinical ChemistryUniversity of GondarGondarEthiopia
  4. 4.College of Medicine and Health Science, School of Biomedical and Laboratory Sciences, Department of Hematology & ImmunohematologyUniversity of GondarGondarEthiopia

Personalised recommendations